INTRODUCTION
============

Since 1818, when an association between psoriasis and joint disorders (psoriatic arthritis) was reported, various other comorbidities have been described, including systemic arterial hypertension (SAH), diabetes mellitus (DM), and cardiovascular disease.^[@r1],[@r2]^ Other comorbidities, such as celiac disease and erectile dysfunction, have been described more recently.^[@r3]-[@r5]^ The clinical manifestations of comorbidities generally appear years after the onset of psoriasis and are more common in severe cases.^[@r6]-[@r8]^ Furthermore, a high frequency of smoking has been noted in psoriasis patients.^[@r9]^ Systematic reviews have consistently demonstrated an increased cardiovascular risk and the need for appropriate prevention measures.^[@r10]-[@r12]^

Alarming rates of obesity and overweight were described in Brazilian psoriasis patients. Moreover, waist circumference and waist-to-hip ratio (WHR) showed a better correlation with the psoriasis severity.^[@r13]^

Although associated comorbidities have long been recognized, there may be a theory-practice dissociation in psoriasis care by dermatologists and there remains an unanswered question over how comorbidities should be screened and who should undertake this task.

This study aimed to determine the prevalences of SAH, DM, dyslipidemia (DLP) and smoking consumption in psoriasis patients (by screening every patient actively), and ascertain the prevalence of other previously diagnosed comorbidities (data from general practitioners\' (GPs) registries). In addition, the features bearing a high correlation with comorbidities were investigated.

METHODS
=======

The data analyzed in the present cross-sectional study were obtained from a sample of 296 psoriasis patients followed up at the Dermatology Service of the Federal University of Bahia, between October 1, 2008 and August 10, 2010. The primary objective of this early study was to evaluate the prevalence of obesity.^[@r13]^ The study was approved by the institution\'s Ethics Committee. The sample size calculation was based on the formula n =z · p · q/d^[@r2]^. It took into account a prevalence (\"p\") of obesity in the state of Bahia, Brazil, of 5%, according to data sourced from the Brazilian Ministry of Health, and given a variation (\"d\") of ±5%. A structured questionnaire was used for data collection. Every psoriasis patient aged ≥ 18 was invited and all consenting consecutive individuals were enrolled. Exclusions motivated by unwillingness to participate in the study were not registered.

Specific procedures:
--------------------

The psoriasis area severity index (PASI) was used to assess psoriasis severity and a score of ≥ 10 was considered moderate-to-severe psoriasis.^[@r14]^Anthropometric evaluations included BMI, waist circumference and WHR.

Diagnoses of SAH and DM were made in accordance with the guidelines established by the American Heart Association. A diagnosis of DLP was made in the presence of two repeated measurements, showing the following levels: triglycerides ≥150 mg/dl, or high-density lipoprotein cholesterol (HDL-C) ≤ 40 mg/dl in men or ≤ 50 mg/dl in women, or low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dl.^[@r15]^

Smoking was evaluated in pack-years, both for current and former smokers. Current smokers were also stratified in accordance to the mean number of cigarettes smoked/day: \< 10 cigarettes/day, 10-20 cigarettes/day or \> 20 cigarettes/day.^[@r16]^

Other comorbidities were obtained by examining the patients\' GP medical records. Criteria and investigations used for their detection are not thoroughly described here (retrospective data).

Data analysis
-------------

Statistical analysis was conducted using the SPSS version 11.5 for Windows. The continuous variables were described as means ± standard deviation of the mean, and the categorical variables as proportions. The distribution of the variables was tested for normality using the Kolmogorov-Smirnov test. Analyses of continuous variables were performed through the Kruskal-Wallis non-parametric test or Student\'s t-test, in accordance to the normality of distribution. Furthermore, analyses of association between the number of comorbidities and the categorical variables were conducted via the chi-square test. A significance level of 5% was set.

RESULTS
=======

A total of 296 psoriasis patients were included, 164 (55.4%) of whom were males. The mean age was 48 ± 14 years and the mean PASI score was 7.9 ± 7.7 (range 0 -- 48). Severe psoriasis was significantly more common in men (37.8%) than in women (26.5%) (p = 0.04). Overall, 28.6% of the patients were obese.^[@r13]^

The frequencies of comorbidities are shown in [table 1](#t1){ref-type="table"}. Excluding obesity and psoriatic arthritis, 85 patients (32%) had one of the comorbidities listed in [table 1](#t1){ref-type="table"}, 32 (10.8%) had two and 25 (8.5%) had three or more comorbidities. Repeat measurements of arterial pressure, fasting glucose and lipid profile revealed no further SAH cases, though 2 more DM cases and 19 more DLP cases were uncovered, in addition to those previously diagnosed by GPs. Consequently, the frequency of DLP increased from 19.5%, in medical records, to 26%.

###### 

The principal comorbidities registered in the study population

  -------------------------------------------------------------------------------------------------
  Comorbidity                                     Absolut\                             Prevalence
                                                  frequency                            
  ----------------------------------------------- ------------------------------------ ------------
  DM                                              28[\*](#TFN1){ref-type="table-fn"}   9.0

  DLP                                             57[\*](#TFN1){ref-type="table-fn"}   19.5

  SAH                                             88[\*](#TFN1){ref-type="table-fn"}   30

  **Hepatopathy (and NAFLD)**                     5                                    1.7

  Human immunodeficiency virus (HIV)              1                                    .3

  Hepatitis C -- clinical hepatitis or serology   2                                    .7

  Hepatitis B -- clinical hepatitis or serology   1                                    .3

  **Stroke**                                      1                                    .3

  **Coronary artery disease**                     7                                    2.7

  Peripheral vascular disease                     5                                    1.7

  Chagas disease                                  3                                    1.0

  **Depression**                                  8                                    2.7

  Diabetic retinopathy                            1                                    .3

  Bipolar disorder                                1                                    .3

  **Osteoarthrosis**                              2                                    .7

  Congestive heart failure                        1                                    .3

  Unspecified cancer                              3                                    1.0

  Vitiligo                                        2                                    .7
  -------------------------------------------------------------------------------------------------

No cases of hypertension, a further 2 cases of DM and 19 cases of DLP were identified following specific screening.

Possible cases of underdiagnosis are marked in bold. A different diagnosis could occur in the same patient. DM -- diabetes; DLP -- dyslipidemia; SAH- hypertension; NAFLD -- non-alcoholic fatty liver disease.

When the variables sex, nail involvement, facial involvement, psoriatic arthritis, PASI score \> 10, mean PASI score, and family history of psoriasis were analyzed, no association was found between any of the variables and the number of comorbidities (p\>0.05). Statistical significance was found for the association between mean age, mean disease duration, higher BMI, WHR, waist circumference and the number of comorbidities (0, 1, 2 or ≥ 3 comorbidities) ([Table 2](#t2){ref-type="table"}).

###### 

Comparison of subgroups of patients according to the number of comorbidities

  Variable                      Number of comorbidities   p-value                                   
  ----------------------------- ------------------------- ------------- ------------- ------------- --------------
  N                             143 (48.5%)               95 (32.2%)    32 (10.8%)    25 (8.5%)      
  Male                          80 (27.1%)                52 (17.6%)    17 (5.8%)     15 (5.1%)     **c2 test**
                                                                                                    **p=0.958**
  Mean age (n, SD)              43.1± 15.5                51.1 ± 11.5   54.5 ± 12.5   58.1 ± 11.4   **F Test**
                                                                                                    **p\<0.00**
  Time of psoriasis (months)    116 ± 96                  152 ± 119     187 ± 156     159 ± 115     **K-W Test**
                                                                                                    **p=0.015**
  Nail involvement              56 (19.0%)                43 (14.6%)    14 (4.7%)     9 (3.1%)      **c2 test**
                                                                                                    **p=0.740**
  Facial involvement            86 (29.4%)                59 (20.1%)    20 (6.8%)     15 (5.1%)     **c2 test**
                                                                                                    **p=0.978**
  Psoriatic arthritis           20 (6.8%)                 17 (5.8%)     4 (1.4%)      5 (1.7%)      **c2 test**
                                                                                                    **p=0.740**
  Inverted psoriasis            1 (3.0%)                  1 (3.0%)      2 (0.7%)      3 (1.0%)      **c2 test**
                                                                                                    **p=0.002**
  PASI score \> 10              50 (16.9%)                32 (10.8%)    7 (2.4%)      8 (2.7%)      **c2 test**
                                                                                                    **p=0.557**
  Family history of psoriasis   30 (10.3%)                21 (7.2%)     12 (4.1%)     8 (2.8%)      **c2 test**
                                                                                                    **p=0.093**
  PASI score                    8.6                       8.1           7.0           7.1           **K-W test**
                                                                                                    **p=0.689**
  BMI                           26.7                      28.7          29.5          30.5          **K-W test**
                                                                                                    **p=0.000**
  Waist-to-hip ratio            0.90                      0.94          0.96          0.98          **K-W test**
                                                                                                    **p=0.000**
  Waist circumference (cm)      89.7                      96.7          100.4         101.6         **K-W test**
                                                                                                    **p=0.000**

Statistically significant differences are marked in bold (Chi-square test; Anova; and Kruskal Wallis test). N=295 (waist circumference missing value for one patient). BMI -- body mass index; PASI -- psoriasis area severity index.

In this study sample, 42.9% of patients reported current or past smoking (14 ± 20 pack-years). There was no statistically significant difference in PASI scores between current/past smokers (n=116) and never-smokers (n=180) (p=0.79). In current smokers, comparison of PASI scores in groups stratified in accordance with daily cigarette consumption revealed no statistically significant differences (p\>0.05).

DISCUSSION
==========

Our study confirms that comorbidities are associated with increased age, psoriasis duration, BMI, WHR and waist circumference. According to the literature, the association between cardiovascular risk factors and psoriasis remains even after adjustments for sex and age.^[@r17]^ Additionally, it was noted that male patients were more likely to have more severe forms of psoriasis, as previously reported, but neither gender nor psoriasis severity were associated with the occurrence of comorbidities.^[@r18],[@r19]^ In contrast, however, previous studies have demonstrated that the greater the psoriasis severity, the stronger the association with comorbidities and, consequently, the higher the patient\'s cardiovascular risk.^[@r20]-[@r22]^

During the follow-up, 19 new DLP cases and 2 new SAH cases were identified, suggesting insufficient screening by GPs. The frequencies found for SAH and DM in this outpatient sample were similar to those found in other studies.^[@r11],[@r17]^

DM incidence in patients with psoriasis correlates positively with BMI, the duration of the disease and/or the use of systemic therapy. ^[@r23]^ DLP has consistently been associated with psoriasis even after adjustment for other known, confounding factors. ^[@r24]-[@r26]^ In this study, DLP active screening increased diagnosis in 33% (19/57) of patients. Despite the impact of retinoids, cyclosporine and anti-TNF-α agents on lipid levels, the authors believe that the majority of undiagnosed cases is due to increased medical surveillance. ^[@r27]-[@r29]^

Epidemiological data from the Brazilian population show the following frequencies: SAH (33.7%); DM (8.0%); smoking (25.2%) and DLP (24.2%).^[@r30]-[@r32]^ Notably, the frequencies for several of the comorbidities evaluated were lower than the rates reported in the literature. For example, the rate of depression -- also associated with an increased risk of cardiovascular disease -- was almost ten times less than the expected.^[@r33]^ This underdiagnosis merits the utmost attention, since in up to 10% of psoriasis cases, it is severe enough to induce suicidal ideation.^[@r34]^ A similar level of underdiagnosis (1.7%) was found for non-alcoholic fatty liver disease, much lower than the level reported in the literature.^[@r27]-[@r29]^

Despite the publication of several population-based studies indicating psoriasis as an independent risk factor for cardiovascular events, motivating the adoption of screening for additional risk factors, it is known that these guidelines are largely ignored. ^[@r35],[@r36]^ In the United States, less than 50% of clinicians are aware of these recommendations.^[@r37]^ In Europe, 27.7% and 44.2% of psoriatic patients with SAH and DLP respectively received no antihypertensive and cholesterol-lowering pharmacotherapy.^[@r38]^

Attempts to associate PASI score with smoking have yielded contradictory results.^[@r9],[@r16]^ No correlation was uncovered between PASI and smoking. Current non-smoker patients might be affected by past smoking, as the effect of smoking is only nulled after 20 years of abstinence, making it difficult to isolate the influence of chronic nicotine abuse on psoriasis severity.^[@r39],[@r40]^

This research has some limitations, including sample size and impossibility to establish causal relationships between correlated variables.

CONCLUSION
==========

This study shows that, despite being known for decades, some comorbidities are underdiagnosed in psoriasis patients. This finding serves as an alert to clinicians, dermatologists and healthcare authorities, emphasizing the need for multidisciplinary management and active screening, which would reduce the impact of these comorbidity associations on patients\' survival, quality of life and mortality, reinforcing the need for changes in healthcare in concordance with growing evidence of theory-practice dissociation in psoriasis management.

The data from this and a previously published study^[@r13]^ enhance our understanding of increases in comorbidities according to age, time of psoriasis, BMI, WHR and waist circumference, which are possible criteria for determining which patients should be screened for comorbidities.
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